<p>博思健康公司（Bausch Health Companies Inc.）（纽约证券交易所代码：BHC）（多伦多证券交易所代码：BHC）（以下简称 “公司”）及其子公司 1261229 B.C. Ltd.（以下简称 “发行人”，与公司合称 “要约方”）今天宣布了其之前宣布的交换要约的最终结果及到期情况，旨在将公司未偿还的 4.875% 优先担保票据（到期日为 2028 年，以下简称 “4.875% 票据”）和 11.00% 优先担保票据（到期日为 2028 年，以下简称 “11.00% 票据”，与 4.875% 票据合称 “现有优先担保票据”）交换为发行人 10.00% 优先担保票据（到期日为 2032 年，以下简称 “新票据”），总额最高可达 16 亿美元（以下简称 “要约”），具体条款详见 2025 年 11 月 24 日的保密交换要约备忘录（以下简称 “交换要约备忘录”）。</p>
<p>交换要约于 2025 年 12 月 23 日下午 5:00（纽约市时间）到期（以下简称 “到期时间”）。根据 D.F. King &amp; Co., Inc.的报告，该公司是要约的交换代理和信息代理，截至到期时间，现有优先担保票据的有效投标总额为 27 亿美元（且未有效撤回），具体见下表。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>现有优先担保票据系列</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Senior Secured Notes</strong></td>
<td><strong>CUSIP 号码 (1)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>(Rule 144A/Reg S)</strong></td>
<td><strong>未偿还本金金额</strong></td>
<td><strong>总对价 (2)(3)</strong></td>
<td><strong>投标本金金额</strong></td>
<td><strong>接受本金金额</strong></td>
<td><strong>发行的新票据总额</strong></td>
<td></td>
</tr>
<tr>
<td>BHC 11.00% 优先</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>担保票据（到期日 2028 年）</td>
<td>071734AQ0 / C07885AL7</td>
<td>$1,774,067,000</td>
<td>$1,020.00</td>
<td>$1,519,477,000</td>
<td>$885,806,000</td>
<td>$903,359,000</td>
</tr>
<tr>
<td>BHC 4.875% 优先</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>担保票据（到期日 2028 年）</td>
<td>071734AN7 /</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C07885AJ2</td>
<td>$1,600,000,000</td>
<td>$873.84</td>
<td>$1,170,539,000</td>
<td>$797,431,000</td>
<td>$696,641,000</td>
<td></td>
</tr>
</tbody>
</table>
<p>(1) 本新闻稿中列出的 CUSIP 号码的正确性或准确性不作任何声明，仅为方便提供。</p>
<p>(2) 以新票据的本金金额作为对价，针对每$1,000 本金金额的现有优先担保票据，前提是这些票据已有效投标并被接受交换。</p>
<p>(3) 11.00% 票据的总对价为每$1,000 本金金额$1,020.00，不包括根据交换要约备忘录规定的以现金支付的应计利息。4.875% 票据的总对价为每$1,000 本金金额$873.84，已调整以反映因 (i) 向已投标并被接受的 4.875% 票据持有人应计利息与 (ii) 新票据自现有 10.00% 优先担保票据的最后利息支付日到（但不包括）要约结算日之间的应计和未支付利息的差额。</p>
<p>根据交换要约备忘录中规定的要约条款和条件，预计在 2025 年 12 月 26 日（以下简称 “结算日”）结算时，将发行约 16 亿美元的新票据，以对应接受要约的现有优先担保票据，具体见上表。所有符合条件的持有人如已向要约方证明其有资格参与要约，并且其现有优先担保票据在结算日被接受交换，将获得现金金额（如适用），该金额等于 (i) 接受要约的现有优先担保票据持有人应计利息与 (ii) 新票据自现有 10.00% 优先担保票据的最后利息支付日到（但不包括）结算日之间的应计和未支付利息的差额。</p>
<p>Sullivan &amp; Cromwell LLP 和 Norton Rose Fulbright Canada LLP 担任法律顾问，Evercore Inc.担任公司的财务顾问。</p>
<p>本新闻稿不构成购买或出售任何证券的要约或邀请，也不应在任何法律管辖区内进行任何证券的出售，若该要约、邀请或出售在该法律管辖区内违法，须在该法律管辖区的证券法下进行注册或资格审查。新票据尚未也将不会根据 1933 年证券法（“证券法”）或任何州证券法进行注册，且在未注册或不适用的注册豁免的情况下，不能在美国提供或出售。新票据尚未也将不会根据适用的加拿大证券法进行公开销售的招股说明书进行资格审查，因此，在加拿大的任何新票据的要约和销售将以免于该证券法的招股说明书要求的方式进行。</p>
<p><strong>关于博思健康</strong></p>
<p>博思健康公司（Bausch Health Companies Inc.）（纽约证券交易所代码：BHC）（多伦多证券交易所代码：BHC）是一家全球多元化的制药公司，通过我们不懈的努力改善医疗保健结果，丰富人们的生活。我们开发、生产和销售一系列产品，主要涉及胃肠病学、肝病学、神经学、皮肤病学、牙科、美容、国际制药和眼健康领域，通过我们对博思 + 朗博（Bausch + Lomb Corporation）的控股权益实现。我们的目标是成为一家全球一体化的医疗保健公司，受到患者、医疗保健专业人士、员工和投资者的信任和重视。有关更多信息，请访问 www.bauschhealth.com。</p>
<p><strong>关于博思健康的前瞻性声明</strong></p>
<p>本新闻稿可能包含适用证券法下的前瞻性陈述，包括 1995 年美国私人证券诉讼改革法案的安全港条款。前瞻性陈述通常可以通过使用 “将”、“预期”、“希望”、“期待”、“打算”、“计划”、“应该”、“可能”、“会”、“相信”、“受制于” 及其变体或类似表达来识别。这些陈述既不是历史事实，也不是未来表现的保证，而是基于管理层当前的期望和信念，并受到某些风险和不确定性的影响，这些风险和不确定性可能导致实际结果与前瞻性陈述中描述的结果有实质性差异。读者被提醒不要对这些前瞻性陈述，包括公司关于要约的计划和期望、要约完成的可能性、公司完成要约的能力及其时机，过度依赖。公司无法保证要约会按计划完成，或根本不会完成。这些前瞻性陈述仅在本日期有效。除非法律或法规要求，公司不承担更新任何前瞻性陈述以反映本新闻稿日期之后的事件、信息或情况或实际结果的义务。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>投资者联系：</strong><br/>Garen Sarafian<br/>ir@bauschhealth.com<br/>(877) 281-6642（免费电话）</td>
<td><strong>媒体联系：</strong><br/>Katie Savastano<br/>corporate.communications@bauschhealth.com<br/>(908) 541-3785</td>
</tr>
</tbody>
</table>
<p><strong>来源：</strong> Bausch Health Companies Inc.</p>
<p>查看原始新闻稿，请访问 ACCESS Newswire</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyMDE4NA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyMDE4NA"/></p>

<p>Bausch Health Companies Inc. 宣布其对未偿还的高级担保票据的交换要约的最终结果和到期情况。该要约于 2025 年 12 月 23 日到期，共有 27 亿美元的票据被提交。预计将在 2025 年 12 月 26 日发行约 16 亿美元的新票据。法律顾问为 Sullivan & Cromwell LLP 和 Norton Rose Fulbright Canada LLP，Evercore Inc. 担任财务顾问</p>

<p>Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the &#34;Company&#34;) and its subsidiary 1261229 B.C. Ltd. (the &#34;Issuer&#34; and, together with the Company, the &#34;Offerors&#34;) today announced the final results and expiration of their previously announced offers to exchange the Company's outstanding 4.875% Senior Secured Notes due 2028 (the &#34;4.875% Notes&#34;) and 11.00% Senior Secured Notes due 2028 (the &#34;11.00% Notes&#34; and together with the 4.875% Notes, the &#34;Existing Senior Secured Notes&#34;) for up to $1.6 billion aggregate principal amount of the Issuer's 10.00% Senior Secured Notes due 2032 (the &#34;New Notes&#34; and, such offers, the &#34;Offers&#34;) , in each case, pursuant to the terms described in a confidential exchange offer memorandum dated November 24, 2025 (the &#34;Exchange Offer Memorandum&#34;).</p>
<div class="lb-trans"><p>博思健康公司（Bausch Health Companies Inc.）（纽约证券交易所代码：BHC）（多伦多证券交易所代码：BHC）（以下简称 “公司”）及其子公司 1261229 B.C. Ltd.（以下简称 “发行人”，与公司合称 “要约方”）今天宣布了其之前宣布的交换要约的最终结果及到期情况，旨在将公司未偿还的 4.875% 优先担保票据（到期日为 2028 年，以下简称 “4.875% 票据”）和 11.00% 优先担保票据（到期日为 2028 年，以下简称 “11.00% 票据”，与 4.875% 票据合称 “现有优先担保票据”）交换为发行人 10.00% 优先担保票据（到期日为 2032 年，以下简称 “新票据”），总额最高可达 16 亿美元（以下简称 “要约”），具体条款详见 2025 年 11 月 24 日的保密交换要约备忘录（以下简称 “交换要约备忘录”）。</p>
</div><p>The Exchange Offers expired at 5:00 p.m., New York City time, on December 23, 2025 (the &#34;Expiration Time&#34;). As reported by D.F. King &amp; Co., Inc., the exchange agent and information agent for the Offers, as of the Expiration Time, an aggregate principal amount of $2.7 billion of Existing Senior Secured Notes had been validly tendered (and not validly withdrawn) in the Offers, as set forth in the table below.</p>
<div class="lb-trans"><p>交换要约于 2025 年 12 月 23 日下午 5:00（纽约市时间）到期（以下简称 “到期时间”）。根据 D.F. King &amp; Co., Inc.的报告，该公司是要约的交换代理和信息代理，截至到期时间，现有优先担保票据的有效投标总额为 27 亿美元（且未有效撤回），具体见下表。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Series of Existing</strong><br/><strong>Senior Secured Notes</strong></td>
<td><strong>CUSIP Number(1)</strong><br/><strong>(Rule 144A/Reg S)</strong></td>
<td><strong>Principal Amount Outstanding</strong></td>
<td><strong>Total Consideration(2)(3)</strong></td>
<td><strong>Principal Amount Tendered</strong></td>
<td><strong>Principal Amount Accepted</strong></td>
<td><strong>Aggregate New Notes Issued</strong></td>
</tr>
<tr>
<td>BHC 11.00% Senior <br/>Secured Notes due 2028</td>
<td>071734AQ0 / C07885AL7</td>
<td>$1,774,067,000</td>
<td>$1,020.00</td>
<td>$1,519,477,000</td>
<td>$885,806,000</td>
<td>$903,359,000</td>
</tr>
<tr>
<td>BHC 4.875% Senior <br/>Secured Notes due 2028</td>
<td>071734AN7 /<br/>C07885AJ2</td>
<td>$1,600,000,000</td>
<td>$873.84</td>
<td>$1,170,539,000</td>
<td>$797,431,000</td>
<td>$696,641,000</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>现有优先担保票据系列</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Senior Secured Notes</strong></td>
<td><strong>CUSIP 号码 (1)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>(Rule 144A/Reg S)</strong></td>
<td><strong>未偿还本金金额</strong></td>
<td><strong>总对价 (2)(3)</strong></td>
<td><strong>投标本金金额</strong></td>
<td><strong>接受本金金额</strong></td>
<td><strong>发行的新票据总额</strong></td>
<td></td>
</tr>
<tr>
<td>BHC 11.00% 优先</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>担保票据（到期日 2028 年）</td>
<td>071734AQ0 / C07885AL7</td>
<td>$1,774,067,000</td>
<td>$1,020.00</td>
<td>$1,519,477,000</td>
<td>$885,806,000</td>
<td>$903,359,000</td>
</tr>
<tr>
<td>BHC 4.875% 优先</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>担保票据（到期日 2028 年）</td>
<td>071734AN7 /</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C07885AJ2</td>
<td>$1,600,000,000</td>
<td>$873.84</td>
<td>$1,170,539,000</td>
<td>$797,431,000</td>
<td>$696,641,000</td>
<td></td>
</tr>
</tbody>
</table>
</div><p>(1) No representation is made as to the correctness or accuracy of the CUSIP numbers listed in this press release or printed on the Existing Senior Secured Notes. They are provided solely for convenience.</p>
<div class="lb-trans"><p>(1) 本新闻稿中列出的 CUSIP 号码的正确性或准确性不作任何声明，仅为方便提供。</p>
</div><p>(2) Consideration in the form of principal amount of the New Notes, per $1,000 principal amount of Existing Senior Secured Notes that are validly tendered and accepted for exchange.</p>
<div class="lb-trans"><p>(2) 以新票据的本金金额作为对价，针对每$1,000 本金金额的现有优先担保票据，前提是这些票据已有效投标并被接受交换。</p>
</div><p>(3) The Total Consideration of $1,020.00 per $1,000 principal amount of 11.00% Notes excludes accrued interest paid in cash as provided in the Exchange Offer Memorandum. The Total Consideration of $873.84 per $1,000 principal amount of 4.875% Notes has been adjusted to reflect the net interest payment resulting from the difference between (i) the accrued interest due to each holder of 4.875% Notes who has tendered 4.875% Notes into the Offer and whose tenders have been accepted in the Offers and (ii) the accrued and unpaid interest due on the New Notes to be issued in respect thereof from the last interest payment date of the existing 10.00% Senior Secured Notes due 2032 to, but not including, the settlement date of the Offers.</p>
<div class="lb-trans"><p>(3) 11.00% 票据的总对价为每$1,000 本金金额$1,020.00，不包括根据交换要约备忘录规定的以现金支付的应计利息。4.875% 票据的总对价为每$1,000 本金金额$873.84，已调整以反映因 (i) 向已投标并被接受的 4.875% 票据持有人应计利息与 (ii) 新票据自现有 10.00% 优先担保票据的最后利息支付日到（但不包括）要约结算日之间的应计和未支付利息的差额。</p>
</div><p>Subject to the terms and conditions of the Offers set forth in the Exchange Offer Memorandum, upon settlement of the Offers, which is currently expected to occur on December 26, 2025 (the &#34;Settlement Date&#34;), there will be approximately $1,600 million principal amount of New Notes issued in respect of the Existing Senior Secured Notes to be accepted in the Offers, as set forth in the table above. All eligible holders who have certified to the Offerors that they are eligible to participate in the Offers and whose Existing Senior Secured Notes are accepted for exchange pursuant to the Offers on the Settlement Date will also be paid a cash amount, if applicable, equal to the difference between (i) the accrued interest due to each holder of Existing Senior Secured Notes accepted in the Offers and (ii) the accrued and unpaid interest due on the New Notes from the last interest payment date of the existing 10.00% Senior Secured Notes due 2032 to, but not including, the Settlement Date.</p>
<div class="lb-trans"><p>根据交换要约备忘录中规定的要约条款和条件，预计在 2025 年 12 月 26 日（以下简称 “结算日”）结算时，将发行约 16 亿美元的新票据，以对应接受要约的现有优先担保票据，具体见上表。所有符合条件的持有人如已向要约方证明其有资格参与要约，并且其现有优先担保票据在结算日被接受交换，将获得现金金额（如适用），该金额等于 (i) 接受要约的现有优先担保票据持有人应计利息与 (ii) 新票据自现有 10.00% 优先担保票据的最后利息支付日到（但不包括）结算日之间的应计和未支付利息的差额。</p>
</div><p>Sullivan &amp; Cromwell LLP and Norton Rose Fulbright Canada LLP acted as legal counsel, and Evercore Inc. acted as financial advisor to the Company.</p>
<div class="lb-trans"><p>Sullivan &amp; Cromwell LLP 和 Norton Rose Fulbright Canada LLP 担任法律顾问，Evercore Inc.担任公司的财务顾问。</p>
</div><p>This press release does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The New Notes have not been and will not be registered under the Securities Act of 1933, as amended (the &#34;Securities Act&#34;) or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. The New Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the New Notes in Canada will be made on a basis, which is exempt from the prospectus requirements of such securities laws.</p>
<div class="lb-trans"><p>本新闻稿不构成购买或出售任何证券的要约或邀请，也不应在任何法律管辖区内进行任何证券的出售，若该要约、邀请或出售在该法律管辖区内违法，须在该法律管辖区的证券法下进行注册或资格审查。新票据尚未也将不会根据 1933 年证券法（“证券法”）或任何州证券法进行注册，且在未注册或不适用的注册豁免的情况下，不能在美国提供或出售。新票据尚未也将不会根据适用的加拿大证券法进行公开销售的招股说明书进行资格审查，因此，在加拿大的任何新票据的要约和销售将以免于该证券法的招股说明书要求的方式进行。</p>
</div><p><strong>About Bausch Health</strong></p>
<div class="lb-trans"><p><strong>关于博思健康</strong></p>
</div><p>Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Visit www.bauschhealth.com for more information.</p>
<div class="lb-trans"><p>博思健康公司（Bausch Health Companies Inc.）（纽约证券交易所代码：BHC）（多伦多证券交易所代码：BHC）是一家全球多元化的制药公司，通过我们不懈的努力改善医疗保健结果，丰富人们的生活。我们开发、生产和销售一系列产品，主要涉及胃肠病学、肝病学、神经学、皮肤病学、牙科、美容、国际制药和眼健康领域，通过我们对博思 + 朗博（Bausch + Lomb Corporation）的控股权益实现。我们的目标是成为一家全球一体化的医疗保健公司，受到患者、医疗保健专业人士、员工和投资者的信任和重视。有关更多信息，请访问 www.bauschhealth.com。</p>
</div><p><strong>Forward‐Looking Statements About Bausch Health</strong></p>
<div class="lb-trans"><p><strong>关于博思健康的前瞻性声明</strong></p>
</div><p>This news release may contain forward-looking statements within the meaning of applicable securities laws, including the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words &#34;will,&#34; &#34;anticipates,&#34; &#34;hopes,&#34; &#34;expects,&#34; &#34;intends,&#34; &#34;plans,&#34; &#34;should,&#34; &#34;could,&#34; &#34;would,&#34; &#34;may,&#34; &#34;believes,&#34; &#34;subject to&#34; and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Readers are cautioned not to place undue reliance on any of these forward-looking statements, including statements of the Company's plans and expectations regarding the Offers, the likelihood of completion of the Offers, the Company's ability to complete the Offers and the timing thereof. The Company cannot assure you that the Offers will be completed on schedule, or at all. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by applicable law or regulation.</p>
<div class="lb-trans"><p>本新闻稿可能包含适用证券法下的前瞻性陈述，包括 1995 年美国私人证券诉讼改革法案的安全港条款。前瞻性陈述通常可以通过使用 “将”、“预期”、“希望”、“期待”、“打算”、“计划”、“应该”、“可能”、“会”、“相信”、“受制于” 及其变体或类似表达来识别。这些陈述既不是历史事实，也不是未来表现的保证，而是基于管理层当前的期望和信念，并受到某些风险和不确定性的影响，这些风险和不确定性可能导致实际结果与前瞻性陈述中描述的结果有实质性差异。读者被提醒不要对这些前瞻性陈述，包括公司关于要约的计划和期望、要约完成的可能性、公司完成要约的能力及其时机，过度依赖。公司无法保证要约会按计划完成，或根本不会完成。这些前瞻性陈述仅在本日期有效。除非法律或法规要求，公司不承担更新任何前瞻性陈述以反映本新闻稿日期之后的事件、信息或情况或实际结果的义务。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Investor Contact:</strong><br/>Garen Sarafian<br/>ir@bauschhealth.com<br/>(877) 281-6642 (toll free)</td>
<td><strong>Media Contact:</strong><br/>Katie Savastano<br/>corporate.communications@bauschhealth.com<br/>(908) 541-3785</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>投资者联系：</strong><br/>Garen Sarafian<br/>ir@bauschhealth.com<br/>(877) 281-6642（免费电话）</td>
<td><strong>媒体联系：</strong><br/>Katie Savastano<br/>corporate.communications@bauschhealth.com<br/>(908) 541-3785</td>
</tr>
</tbody>
</table>
</div><p><strong>SOURCE:</strong> Bausch Health Companies Inc.</p>
<div class="lb-trans"><p><strong>来源：</strong> Bausch Health Companies Inc.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新闻稿，请访问 ACCESS Newswire</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEyMDE4NA" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1120184"/></p>

Bausch Health 宣布交换要约的最终结果及其到期情况 | BHC 股票新闻